Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics
Tobira Therapeutics

3.26.14
Tobira Therapeutics Appoints Chairman Laurent Fischer, MD, Chief Executive Officer and Christopher Peetz Chief Financial Officer

11.4.13
Tobira Therapeutics Presents Data Supporting Anti-Fibrotic Activity of Cenicriviroc in Liver Disease Models at The Liver Meeting 2013

10.17.13
Tobira Therapeutics Presents Positive 48-Week Data from Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection at the 14th European AIDS Conference

10.4.13
Tobira Therapeutics Announces Publication of Cenicriviroc Formulation Improvement Providing Platform for Single Tablet and Fixed-­‐Dose Combinations

3.5.13
Tobira Therapeutics Presents Positive Phase 2b Clinical Results for Cenicriviroc in Treatment-­‐Naïve HIV Infection in Late Breaker Session at CROI 

1.7.13
Tobira Therapeutics Announces Positive 24 - Week Primary Analysis from Phase 2b Trial of Cenicriviroc in Treatment - Naive HIV Infection

12.19.12
Tobira Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference

10.25.12
Tobira Therapeutics Receives Additional US Patent on Cenicriviroc

9.10.12
Tobira Therapeutics Completes Senior Management Team with Key Strategic Hires in Finance, Clinical and Pharmaceutical Sciences

4.5.12
Antoun Nabhan, JD, Joins Tobira Therapeutics Leadership Team

3.7.12
Pharmacokinetics (PK) of Cenicriviroc (CVC) following 100 or 200 MG Once-Daily Dosing with Open-label Tenofovir/Emtricitabine (TDF/FTC) in HIV-1-Infected Subjects Enrolled in a Phase 2b Study

1.5.12
Tobira Therapeutics Continues Management Team Expansion

8.8.11
Tobira Therapeutics Announces Key Management Team Additions

7.19.11
Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults

6.22.11
Tobira Therapeutics Initiates Phase IIb Trial of Cenicriviroc, a Novel CCR5/CCR2 Antagonist for the Treatment of HIV Infection

4.4.11
Tobira Therapeutics Appoints Andrew Hindman President and Chief Executive Officer

2.28.11
Tobira Therapeutics Reports Encouraging Pharmacokinetic, Bioavailability and Safety Results from Studies of Cenicriviroc

9.29.10
Tobira Announces $31 Million Series B Raise; Phase llb Plans

7.19.10
Tobira's Next-Generation Once-Daily CCR5/CCR2 Antagonist Demonstrates Potent CCR2 Inhibition, Antiviral Activity, Safety and Tolerability In Treatment-Experienced Patients With HIV; TBR-652 Phase IIa Data Presented at XVIII International AIDS Conference Showcase Potentially Important Anti-Inflammatory Benefits

2.17.10
Pharmacokinetic/Pharmacodynamic Data Support Further Development Of Tobira's Next-Generation CCR5 Receptor Antagonist

2.17.10
Tobira's Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability In Treatment-Experienced Patients With HIV

11.12.09
Tobira Therapeutics Inc. Announce Presentation of TBR-652 Data at European AIDS Conference

7.22.09
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 For The Treatment of HIV

6.4.09
Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board

4.8.09
Tobira Therapeutics Inc. Initiates Proof of Concept Study With TAK-652 For The Treatment of HIV

8.18.08
Tobira Therapeutics Inc. Receives US Patent for TBR-652

6.30.08
Tobira Therapeutics Inc. Announces Leadership Team Possessing Over 130 Years of Cumulative Expertise

Tobira Therapeutics
Tobira Therapeutics
  Digital Endeavor Websites